Up-to-date Information on
Waldenström’s macroglobulinemia



The state-of-the-art glossary for Waldenström’s macroglobulinemia.


Rituximab in the glossary for Waldenström's macroglobulinemia

Rituximab is a chimeric monoclonal antibody anti-CD20 antibody

Rituximab is a chimeric monoclonal antibody against the protein CD20, which is primarily found on the surface of immune system B cells. When it binds to this protein, it triggers cell death. Rituximab is primarily used to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia, Wegener's granulomatosis, pemphigus vulgaris, and rheumatoid arthritis. Rituximab was approved for medical use in 1997. It is on the World Health Organization's List of Essential Medicines. Rituximab is authorized for use in the EU (rituximab SmPC).

Glossary overview